• Miplyffa (arimoclomol), the first ever medication specifically approved for Niemann-Pick disease type C, is now available from Zevra Therapeutics (NASDAQ:ZVRA).
• The drug is approved for use in combination with Johnson & Johnson's (JNJ) Zavesca (miglustat) for the treatment of patients two years and older. Zavesca is approved for Gaucher disease.
• Miplyffa works by boosting the activation of the transcription factors EB (TFEB) and E3 (TFE3), leading to the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes.
• The U.S. FDA approved Miplyffa in September.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。